Clinical trial · Observational
Telomere and Telomerase
NCT01176422CI-TRIAL-00025409withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of resources; no patient enrollment
Summary
Brief summary (as posted)
Researchers hope to determine if the DNA is shortened in your body and determine if there is an increase in the protein that shortens DNA called telomerase.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- advanced Myelodysplastic Syndrome or acute myeloid leukemia
- description
- advanced MDS and AML with/without associated cytogenetic abnormality
- interventionNames
- Genetic: Blood sample
Primary outcomes (1)
- measure
- Identification and resolution of telomere dysfunction-induced focus (TIF) and normalization of telomerase activity
- timeFrame
- up to 24 weeks
- description
- Advancing myelodysplasia is associated with progressive telomere attrition and clonal chromosomal evolution. Based on this hypothesis, we expect to see identification of TIF by immunostaining and increase in Telomerase activity in peripheral blood granulocytes of patients with advanced Myelodysplastic Syndrome (MDS) and acute myeloid leukemia. We also expect to see resolution of TIF and normalization of telomerase activity upon treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of advanced Myelodysplastic Syndrome (MDS) or acute myeloid leukemia * must be 18 years of age * must be able to give written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.